Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.62 AUD -1.01% Market Closed
Market Cap: 8.2B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Gross Margin
Telix Pharmaceuticals Ltd

61.8%
Current
63%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61.8%
=
Gross Profit
399m
/
Revenue
645.7m

Gross Margin Across Competitors

Country AU
Market Cap 8.2B AUD
Gross Margin
62%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.2B USD
Gross Margin
67%
Country US
Market Cap 142B USD
Gross Margin
60%
Country US
Market Cap 115B USD
Gross Margin
78%
Country US
Market Cap 101.6B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 78.5B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Market Cap
8.2B AUD
Industry
Biotechnology
Economic Moat
Wide

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
16.51 AUD
Overvaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
61.8%
=
Gross Profit
399m
/
Revenue
645.7m
What is the Gross Margin of Telix Pharmaceuticals Ltd?

Based on Telix Pharmaceuticals Ltd's most recent financial statements, the company has Gross Margin of 61.8%.